VICTORIA EVELYN: Open Payments
NPI 1114332020 · BOULDER, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,999 in 100 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $1,798 · 2025 $1,999
Food & beverage: $1,999
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 33 | $536 |
| Gilead Sciences, Inc. | 14 | $281 |
| QOL Medical, LLC | 11 | $213 |
| Regeneron Healthcare Solutions, Inc. | 5 | $129 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $91 |
| Celltrion USA Inc. | 3 | $91 |
| Lilly USA, LLC | 4 | $85 |
| Phathom Pharmaceuticals, Inc. | 4 | $81 |
| Janssen Biotech, Inc. | 3 | $76 |
Products named: RINVOQ, Sucraid, DUPIXENT, LINZESS, XIFAXAN, SKYRIZI, ENTYVIO, VEGZELMA.
Industry payments across CO — which companies pay providers there.
